RGEN
What one share of Repligen holds
Biological Products, (No Diagnostic Substances)
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.
Repligen’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $13.86 |
|---|---|
| Profit | $0.73 |
| Capex (buildings and equipment) | $0.40 |
| Free cash flow | $1.98 |
| Cash and investments | $14.36 |
| Debt | $9.77 |
| Book value | $37.43 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $3.07 | $0.34 | $0.13 | $0.09 | — | $4.99 |
| 2017 | $3.61 | $0.72 | $0.14 | $0.31 | — | $13.57 |
| 2018 | $4.27 | $0.37 | $0.23 | $0.49 | — | $14.02 |
| 2019 | $5.49 | $0.44 | $0.38 | $0.99 | — | $20.35 |
| 2020 | $6.80 | $1.11 | $0.42 | $0.75 | — | $27.92 |
| 2021 | $11.71 | $2.24 | $1.17 | $0.91 | — | $31.63 |
| 2022 | $13.95 | $3.24 | $1.48 | $1.52 | — | $34.39 |
| 2023 | $11.22 | $0.63 | $0.64 | $1.38 | — | $35.23 |
| 2024 | $11.34 | −$0.46 | $0.46 | $2.68 | — | $35.17 |
| 2025 | $13.05 | $0.86 | $0.42 | $1.66 | — | $37.39 |